Literature DB >> 6135026

Ocular toxicity of high-dose intravenous desferrioxamine.

S C Davies, R E Marcus, J L Hungerford, M H Miller, G B Arden, E R Huehns.   

Abstract

Desferrioxamine was given intravenously, at higher doses than previously reported, to counter the effects of transfusion-induced iron overload in four patients with beta thalassaemia major. In two of them retinal abnormalities developed, presenting with night blindness and field defects, which improved on withdrawal of the drug.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6135026     DOI： 10.1016/s0140-6736(83)90170-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  33 in total

1.  Macular vitelliform lesion in desferrioxamine-related retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman; Anastasios Anastasakis; Martin Lindeman
Journal:  Doc Ophthalmol       Date:  2010-06-09       Impact factor: 2.379

2.  Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

Authors:  T Y Y Lai; G K Y Lee; W-M Chan; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

3.  Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.

Authors:  V De Sanctis; A Pinamonti; A Di Palma; M Sprocati; G Atti; M R Gamberini; C Vullo
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

4.  Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings.

Authors:  A H Rahi; J L Hungerford; A I Ahmed
Journal:  Br J Ophthalmol       Date:  1986-05       Impact factor: 4.638

5.  Haemochromatosis presenting as congestive cardiac failure.

Authors:  J Porter; N Cary; P Schofield
Journal:  Br Heart J       Date:  1995-01

6.  Ocular changes in patients undergoing long-term desferrioxamine treatment.

Authors:  G B Arden; B Wonke; C Kennedy; E R Huehns
Journal:  Br J Ophthalmol       Date:  1984-12       Impact factor: 4.638

7.  Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.

Authors:  Rashi Taneja; Pankaj Malik; Mamta Sharma; Mahesh C Agarwal
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

Review 8.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048

9.  High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.

Authors:  H Breithaupt; H Heckers; H Pralle; W Guttmann; H Bleyl; V Graef; G Jundt
Journal:  Blut       Date:  1986-04

10.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.